company background image
CCXI

ChemoCentryx NasdaqGS:CCXI Stock Report

Last Price

US$22.79

Market Cap

US$1.6b

7D

18.9%

1Y

137.6%

Updated

21 May, 2022

Data

Company Financials +
CCXI fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CCXI Stock Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.

ChemoCentryx Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ChemoCentryx
Historical stock prices
Current Share PriceUS$22.79
52 Week HighUS$42.16
52 Week LowUS$9.53
Beta1.95
1 Month Change9.15%
3 Month Change-24.21%
1 Year Change137.64%
3 Year Change94.62%
5 Year Change230.29%
Change since IPO107.18%

Recent News & Updates

Shareholder Returns

CCXIUS BiotechsUS Market
7D18.9%1.4%-2.7%
1Y137.6%-21.7%-12.9%

Return vs Industry: CCXI exceeded the US Biotechs industry which returned -22.1% over the past year.

Return vs Market: CCXI exceeded the US Market which returned -12.7% over the past year.

Price Volatility

Is CCXI's price volatile compared to industry and market?
CCXI volatility
CCXI Average Weekly Movement12.2%
Biotechs Industry Average Movement12.4%
Market Average Movement7.9%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CCXI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: CCXI's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996178Thomas Schallhttps://www.chemocentryx.com

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis.

ChemoCentryx Fundamentals Summary

How do ChemoCentryx's earnings and revenue compare to its market cap?
CCXI fundamental statistics
Market CapUS$1.62b
Earnings (TTM)-US$140.65m
Revenue (TTM)US$27.33m

59.4x

P/S Ratio

-11.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CCXI income statement (TTM)
RevenueUS$27.33m
Cost of RevenueUS$77.56m
Gross Profit-US$50.22m
Other ExpensesUS$90.43m
Earnings-US$140.65m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.98
Gross Margin-183.77%
Net Profit Margin-514.64%
Debt/Equity Ratio9.6%

How did CCXI perform over the long term?

See historical performance and comparison

Valuation

Is ChemoCentryx undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: CCXI ($22.79) is trading below our estimate of fair value ($205.85)

Significantly Below Fair Value: CCXI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CCXI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CCXI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CCXI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CCXI is overvalued based on its PB Ratio (6.3x) compared to the US Biotechs industry average (1.5x).


Future Growth

How is ChemoCentryx forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


70.9%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CCXI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: CCXI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CCXI's is expected to become profitable in the next 3 years.

Revenue vs Market: CCXI's revenue (49.6% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: CCXI's revenue (49.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CCXI is forecast to be unprofitable in 3 years.


Past Performance

How has ChemoCentryx performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-45.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CCXI is currently unprofitable.

Growing Profit Margin: CCXI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CCXI is unprofitable, and losses have increased over the past 5 years at a rate of 45.3% per year.

Accelerating Growth: Unable to compare CCXI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CCXI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: CCXI has a negative Return on Equity (-54.36%), as it is currently unprofitable.


Financial Health

How is ChemoCentryx's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CCXI's short term assets ($351.6M) exceed its short term liabilities ($68.8M).

Long Term Liabilities: CCXI's short term assets ($351.6M) exceed its long term liabilities ($112.9M).


Debt to Equity History and Analysis

Debt Level: CCXI has more cash than its total debt.

Reducing Debt: Insufficient data to determine if CCXI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CCXI has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CCXI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is ChemoCentryx current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CCXI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CCXI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CCXI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CCXI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CCXI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Thomas Schall (62 yo)

25.5yrs

Tenure

US$8,978,084

Compensation

Dr. Thomas J. Schall, Ph.D. Founded ChemoCentryx Inc. in November 1996 and has been its Chief Executive Officer, President and Director since 1997. Dr. Schall focuses on the discovery and development of ch...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD8.98M) is above average for companies of similar size in the US market ($USD5.43M).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CCXI's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: CCXI's board of directors are considered experienced (8.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.1%.


Top Shareholders

Company Information

ChemoCentryx, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: ChemoCentryx, Inc.
  • Ticker: CCXI
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.622b
  • Shares outstanding: 71.19m
  • Website: https://www.chemocentryx.com

Number of Employees


Location

  • ChemoCentryx, Inc.
  • 835 Industrial Avenue
  • Suite 600
  • San Carlos
  • California
  • 94070
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/21 00:00
End of Day Share Price2022/05/20 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.